Tech Company Financing Transactions

AmpliMed Funding Round

AmpliMed secured a $5 million Series B funding round on 6/16/2005. Backers included Biotech Insight Ventures, DPEC Partners and Solstice Capital.

Transaction Overview

Company Name
Announced On
6/16/2005
Transaction Type
Venture Equity
Amount
$5,000,000
Round
Series B
Investors

Biotech Insight Ventures (Joel Smolen)

DPEC Partners (Scott Mathis)

Solstice Capital (Scott Mathis)

Valley Ventures (Jock Holliman)

Proceeds Purpose
This funding will help us to continue these efforts as well as research additional late-stage clinical development opportunities.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1730 E River Rd. 100-A
Tucson, AZ 85718
USA
Email Address
Not Recorded
Overview
AmpliMed Corporation, a clinical-stage pharmaceutical company founded by world-renowned oncologists, has a lead compound, Amplimexon, in Phase II clinical trials, with early evidence of efficacy and low levels of toxicity.
Profile
AmpliMed LinkedIn Company Profile
Social Media
AmpliMed Company Twitter Account
Company News
AmpliMed News
Facebook
AmpliMed on Facebook
YouTube
AmpliMed on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Robert Dorr
  Robert Dorr LinkedIn Profile  Robert Dorr Twitter Account  Robert Dorr News  Robert Dorr on Facebook


 

 

Browse more venture capital transactions:

Prev: 6/15/2005: Parallels venture capital transaction
Next: 6/16/2005: AmpliMed venture capital transaction

 

Share this article

 


About Our VC Transactions Data

We do our best to report on every notable VC transaction. VC transactions reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary